This study was conducted in the period of July to November 2018. Trial registrationĮthical issues approved by the Kangwon National University Institutional Review Board with a number of KWNUIRB-3-005 and CRIS code Number of KCT0005078 were retrospectively registered on. Thus, its supplementation may contribute to overall oral health. We reported an improvement in BOP and microbial environment and demonstrated the antimicrobial activity of oraCMU against F. Besides, there were significant differences at 8 weeks in levels of Staphylococcus aureus. There was a significant change in levels of Fusobacterium nucleatum at four and 8 weeks between the two groups. Oral bacteria were observed to be fewer in the probiotic group. No significant inter-group differences in PD, GI, and PI were observed during the intervention. There were statistically significant differences in BOP of the maxilla buccal and lingual sites between the groups during the intervention ( P < 0.05). ResultsīOP improved more in the probiotic group over 8 weeks. In addition, microbiota in the gingival sulcus were analysed. Periodontal clinical parameters included bleeding on probing (BOP), probing depth (PD), gingival index (GI), and plaque index (PI). The tablets were administered once daily for 8 weeks. All subjects received dental scaling and root planing, and were randomly assigned to either probiotic or placebo groups. MethodsĪ randomised, double-blind, placebo-controlled trial was conducted in 92 adults without periodontitis (20–39 years of age). The present study aimed to evaluate the effects of oraCMU-containing tablets on periodontal health and oral microbiota. Weissella cibaria CMU (oraCMU) has been commercially available in the market for several years as oral care probiotics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |